CA2448076A1 — 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
Assigned to Yamanouchi Pharmaceutical Co Ltd · Expires 2002-11-28 · 23y expired
What this patent protects
It is intended to provide vascular endothelial growth factor (VEGF) inhibito rs useful as drugs, in particular, remedies for diseases in which angiogenesis participates (for example, solid cancer and diabetic retinopathy). Namely, novel 3-quinoline-2(1H)-ylideneindolin-2-one deri…
USPTO Abstract
It is intended to provide vascular endothelial growth factor (VEGF) inhibito rs useful as drugs, in particular, remedies for diseases in which angiogenesis participates (for example, solid cancer and diabetic retinopathy). Namely, novel 3-quinoline-2(1H)-ylideneindolin-2-one derivatives represented by the following general formula (I) or salts thereof have excellent effects of inhibiting VEGF and angiogenesis and an antitumor effect and, therefore, are useful as appropriate VEGF inhibitors, angiogenesis inhibitors and anticance r agents: (I).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.